Publications

Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center in Herat, Afghanistan.

Abstract

Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), such as Afghanistan are sparse.

Klein A Bastard M Hemat H Singh S Muniz B Manangama G Alayyan A Tamanna AH Barakzaie B Popal N Kakar MAZ Poulet E Finger F
PLOS global public health 2023 ; 3(8); . doi: 10.1371/journal.pgph.0001687. Epub 2023 08 24

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications.

Abstract

Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

Rich ML Khan U Zeng C LaHood A Franke MF Atwood S Bastard M Burhan E Danielyan N Dzhazibekova PM Gadissa D Ghafoor A Hewison C Islam MS Kazmi E Khan PY Lecca L Maama LB Melikyan N Naing YY Philippe K Saki NA Seung KJ Skrahina A Tefera GB Varaine F Vilbrun SC Võ L Mitnick CD Huerga H
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023 Jun 01; 27(6); . doi: 10.5588/ijtld.22.0613. Epub 2023 05 29

Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data.

Abstract

BACKGROUND: Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily available.

Broger T Koeppel L Huerga H Miller P Gupta-Wright A Blanc FX Esmail A Reeve BWP Floridia M Kerkhoff AD Ciccacci F Kasaro MP Thit SS Bastard M Ferlazzo G Yoon C Van Hoving DJ Sossen B García JI Cummings MJ Wake RM Hanson J Cattamanchi A Meintjes G Maartens G Wood R Theron G Dheda K Olaru ID Denkinger CM
The Lancet. Global health 2023 Jun ; 11(6); . doi: 10.1016/S2214-109X(23)00135-3. Epub 2023 05 22

Community-based COVID-19 active case finding and rapid response in the Democratic Republic of the Congo: Improving case detection and response.

Abstract

A community-based coronavirus disease (COVID-19) active case-finding strategy using an antigen-detecting rapid diagnostic test (Ag-RDT) was implemented in the Democratic Republic of Congo (DRC) to enhance COVID-19 case detection.

Otshudiema JO Folefack GLT Nsio JM Kakema CH Minikulu L Bafuana A Kosianza JB Mfumu AK Nkwembe E Munyeku-Bazitama Y Makiala-Mandanda S Guinko N Mbuyi G Tshilumbu JK Saidi GN Umba-di-Masiala MS Ebondo AK Mutonj JJ Kalombo S Kabeya J Mawanda TK Bile FN Kasereka GK Mbala-Kingebeni P Ahuka-Mundeke S Karamagi HC Fai KN Djiguimde AP
PloS one 2023 ; 18(5); . doi: 10.1371/journal.pone.0278251. Epub 2023 05 18

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

Abstract

BACKGROUND: Current supply shortages constrain yellow fever vaccination activities, particularly outbreak response.

Juan-Giner A Namulwana ML Kimathi D Grantz KH Fall G Dia M Bob NS Sall AA Nerima C Sahani MK Mulogo EM Ampeire I Hombach J Nanjebe D Mwanga-Amumpaire J Cummings DAT Bejon P Warimwe GM Grais RF
The Lancet. Infectious diseases 2023 Apr 28; . doi: 10.1016/S1473-3099(23)00131-7. Epub 2023 04 28

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.

Abstract

BACKGROUND: Evidence indicates that fractional doses of yellow fever vaccine are safe and sufficiently immunogenic for use during yellow fever outbreaks.

Kimathi D Juan-Giner A Orindi B Grantz KH Bob NS Cheruiyot S Hamaluba M Kamau N Fall G Dia M Mosobo M Moki F Kiogora K Chirro O Thiong'o A Mwendwa J Guantai A Karanja HK Gitonga J Mugo D Ramko K Faye O Sanders EJ Grais RF Bejon P Warimwe GM
The Lancet. Infectious diseases 2023 Apr 28; . doi: 10.1016/S1473-3099(23)00114-7. Epub 2023 04 28

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective.

Abstract

Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results.

Rodriguez CA Lodi S Horsburgh CR Mitnick CD Bastard M Huerga H Khan U Rich M Seung KJ Atwood S Manzur-Ul-Alam M Melikyan N Mpinda S Myint Z Naidoo Y Petrosyan O Salahuddin N Sarfaraz S Vilbrun SC Yae K Achar J Ahmed S Algozhina E Beauchamp J de Guadelupe Perea Moreno S Gulanbaeva M Gergedava M Indah Sari CY Hewison C Khan P Franke MF
PLOS global public health 2023 ; 3(4); . doi: 10.1371/journal.pgph.0000818. Epub 2023 04 28
Campbell JR Chan ED Anderson LF Bonnet M Brode SK Cegielski JP Guglielmetti L Singla R Fox GJ Skrahina A Rodrigues D Kuksa L Viiklepp P Menzies D
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2023 Apr 01; 27(4); . doi: 10.5588/ijtld.22.0678. Epub 2023 04 10